@article{e52c029cca374c328247effcd358ad07,
title = "Childhood maltreatment and impact on clinical features of major depression in adults",
abstract = "Objectives: This study examined: 1) the prevalence of childhood maltreatment (CMT) in individuals with chronic and/or recurrent depression, 2) the association between CMT and depressive symptoms, 3) the link between CMT and worse clinical presentation of depression, 4) the effects of accumulation of different types of CMT, and 5) the relationship between the age at CMT and depression. Methods: We analyzed the baseline data of 663 individuals from the CO-MED study. CMT was determined by a brief self-reported questionnaire assessing sexual abuse, emotional abuse, physical abuse, and neglect. Correlational analyses were conducted. Results: Half of the sample (n = 331) reported CMT. Those with CMT had higher rates of panic/phobic, cognitive and anhedonic symptoms than those without CMT. All individual types of maltreatment were associated with a poorer clinical presentation including: 1) earlier MDD onset; 2) more severe MDD, 3) more suiccidality, 4) worse quality of life, and functioning, and 5) more psychiatric comorbidities. Clinical presentation was worse in participants who reported multiple types of CMT. Conclusions: In chronic and/or recurrent depression, CMT is common, usually of multiple types and is associated with a worse clinical presentation in MDD. The combination of multiple types of CMT is associated with more impairment.",
keywords = "Childhood maltreatment, Childhood trauma, Depression, Early life adversities, Major depression, Major depressive disorder",
author = "Medeiros, {Gustavo C.} and Prueitt, {William L.} and Abu Minhajuddin and Patel, {Shirali S.} and Czysz, {Andrew H.} and Furman, {Jennifer L.} and Mason, {Brittany L.} and Rush, {A. John} and Jha, {Manish K.} and Trivedi, {Madhukar H.}",
note = "Funding Information: The CO-MED trial (NCT00590863) was funded by NIMH (N01 MH-90,003- Trivedi MH and Rush AJ PIs), and in part by the Hersh Foundation (Trivedi MH PI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Forest Pharmaceuticals, GlaxoSmithKline, Organon, and Wyeth Pharmaceuticals provided medications for this trial at no cost. Research reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number R25MH101078 (Trivedi MH PI). Funding Information: Dr. Rush has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC., Emmes Corp., Holmusk Inc., Johnson and Johnson (Janssen), Liva-Nova; speaking fees from Liva-Nova; and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is named co-inventor on two patents: U.S. Patent No. 7795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. Dr. Jha has received contract research grants from Acadia Pharmaceuticals and Janssen Research & Development, and honoraria for CME presentations from North American Center for Continuing Medical Education and Global Medical Education. Dr. Trivedi has served as an adviser or consultant for Abbott Laboratories, Abdi Ibrahim, Akzo (Organon Pharmaceuticals), Alkermes, AstraZeneca, Axon Advisors, Bristol-Myers Squibb, Cephalon, Cerecor, CME Institute of Physicians, Concert Pharmaceuticals, Eli Lilly, Evotec, Fabre Kramer Pharmaceuticals, Forest Pharmaceuticals, GlaxoSmithKline, Janssen Global Services, Janssen Pharmaceutica Products, Johnson & Johnson PRD, Libby, Lundbeck, Meade Johnson, MedAvante, Medtronic, Merck, Mitsubishi Tanabe Pharma Development America, Naurex, Neuronetics, Otsuka Pharmaceuticals, Pamlab, Parke-Davis Pharmaceuticals, Pfizer, PgxHealth, Phoenix Marketing Solutions, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche Products, Sepracor, Shire Development, Sierra, SK Life and Science, Sunovion, Takeda, Tal Medical/Puretech Venture, Targacept, Transcept, VantagePoint, Vivus, and Wyeth-Ayerst Laboratories; he has received grants or research support from the Agency for Healthcare Research and Quality, Cyberonics, NARSAD, NIDA, and NIMH. Drs. Medeiros, Prueitt, Minhajuddin, Patel, Czysz, Furman and Mason have no conflicts to report. Funding Information: We thank the trial participants and the clinical staff at each clinical site. Without them the project would not have been possible. Finally, the authors appreciate the support given by the Jordan Elizabeth Harris Foundation and the Rees-Jones Foundation. ",
year = "2020",
month = nov,
doi = "10.1016/j.psychres.2020.113412",
language = "English (US)",
volume = "293",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
}